In early July 2026, a third-generation farmer in Reedley, California, began giving away his entire nectarine harvest for free rather than let it rot in the orchard. Over the course of about a week, more than 6,000 people showed up to Cesar Mora’s farm and carried off an estimated 182,000 pounds of fruit. The giveaway, organised under the banner “No Nectarines Wasted,” made national news. What made it necessary is a contract dispute that reached a jury verdict roughly a week ago, and buried inside that dispute is a detail worth pulling out on its own: the “exclusive” fruit variety at the centre of the whole fight was never actually patented.
How a licensing deal turned into a lawsuit
In 2017, Mora signed an agreement with Giumarra Brothers Fruit Company, one of the largest produce distributors in the United States, to grow a specialty white-flesh nectarine variety called the Monalise. Under the arrangement, Mora would grow the fruit and Giumarra would handle packing, marketing, and sales, in exchange for a share of the proceeds. Mora has said that arrangement didn’t work out the way it was described to him: he has alleged that up to half of his 2020 crop was discarded rather than sold, cutting into his return, and that in 2022 Giumarra sold nectarines to Taiwan despite a contract term limiting sales to the US and Canada, a claim Giumarra disputes.
By 2023, Mora had sold part of his crop to a different fruit packer instead. Giumarra sued him for breach of contract. Mora countersued, alleging fraud, unfair business practices, and breach of fiduciary duty. A Fresno County Superior Court judge dismissed two of Mora’s counterclaims as filed too late and allowed Giumarra’s core breach of contract claim to proceed, a decision the judge noted held regardless of whether the fruit was covered by a patent. The case went before a jury on July 20, 2026. After a two-week trial, the jury found that Mora had breached his contract, but awarded Giumarra zero dollars in damages, and separately rejected Mora’s claims against the company. A judge had earlier ordered Mora to destroy his Monalise trees.
The part that’s easy to miss in the headlines
Much of the press coverage described this as a dispute over a “patented” or “exclusive-rights” fruit variety, and Mora’s own attorneys stated in court filings that Giumarra had represented the Monalise as an exclusive variety over which it held “patents and related legal rights.” But Giumarra’s own court filings say otherwise: the company stated directly that the Monalise is not covered by a US plant patent.
That distinction matters more than it might first appear. US law offers two separate statutory paths for protecting a new plant variety: the Plant Patent Act of 1930, which covers new varieties of plants reproduced asexually, through grafting or cuttings, the standard method for propagating fruit trees, and the Plant Variety Protection Act of 1970, which covers new varieties reproduced sexually, largely through seed. A formally patented plant variety gives its owner an exclusive legal right, enforceable against anyone who reproduces or sells it without authorisation, for a fixed term. Without either form of protection, “exclusivity” over a plant variety has to come from somewhere else.
In this case, that somewhere else was ordinary contract law. Giumarra’s control over who could grow and sell the Monalise wasn’t backed by a patent at all; it rested entirely on the licensing agreement Mora signed in 2017. The company’s position and its eventual partial win in court turned on breach of contract, not on any exclusive right created by federal IP statute.
Why this is a useful thing to understand, beyond one farmer’s case
This case is a clear, real-world illustration of something that gets blurred constantly, both in casual conversation and in press coverage: not every claim of “exclusive rights” over an innovation, biological or otherwise, is actually backed by a registered IP right. Contracts can create exclusivity too, and in industries like specialty agriculture, they often do a lot of the same practical work a patent would, controlling who can grow, sell, or distribute something, without ever going through a patent office at all.
The tradeoffs are different, though. A plant patent is a public, registered right with a fixed term, open to legal challenge on defined statutory grounds like novelty. A private licensing contract is exactly that: private, negotiated between two unequal parties, and enforceable primarily through contract law rather than IP law, which shifts the legal terrain considerably, as this case shows. Mora didn’t lose because he infringed a patent. He lost, in part, because he broke a contract, a very different legal claim with different defences available and a different burden of proof.
For a grower entering one of these arrangements, understanding that difference at the outset, whether the “exclusivity” they’re being asked to respect rests on a registered plant patent or purely on the terms of a private agreement, is not a small technicality. It shapes what rights they actually have, and what leverage the other side actually holds, long before any dispute reaches a courtroom.
Sources consulted for this piece: The Associated Press (via the The Press Democrat , Boston Globe Media , The Washington Post , ABC News , and U.S. News & World Report ), NBC Bay Area , ABC7 Los Angeles , ABC30 Fresno, The Business Journal (Fresno), Law Commentary , KVPR / Valley Public Radio , and the Mid Valley Times . This piece was independently researched and written; no text has been reproduced from any source beyond the short attributed quotes above.
